ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,189Medicare Part D Prescriptions Filled, Including Refills

Rank: 289 out of 2429

$426K Total Retail Price of All Prescriptions

Rank: 386 out of 2429

282 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
49% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Illinois
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 282 patients filled at least one prescription for a schedule two drug, compared to an average of 2%.

Schedule Three
Controlled Substances

10% of this provider’s 282 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

2% of this provider’s 8,614 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$46 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

33 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Illinois
LEVOTHYROXINE SODIUM 488 455 1 3
WARFARIN SODIUM 405 321 2 11
FUROSEMIDE 366 350 3 5
OMEPRAZOLE 299 284 4 7
POTASSIUM CHLORIDE 276 259 5 14
SIMVASTATIN 268 249 6 1
LISINOPRIL 238 227 7 2
IPRATROPIUM-ALBUTEROL 237 237 8 120
METOPROLOL TARTRATE 229 223 9 9
DONEPEZIL HCL 193 193 10 26
NAMENDA 178 178 11 35
AMLODIPINE BESYLATE 156 144 12 4
MIRTAZAPINE 151 151 13 63
SERTRALINE HCL 134 122 14 23
METOPROLOL SUCCINATE 129 124 15 12
TRAMADOL HCL 119 119 16 17
GABAPENTIN 117 114 17 18
CITALOPRAM HBR 108 108 18 19
METFORMIN HCL 108 101 18 8
ALENDRONATE SODIUM 107 107 20 20
LOSARTAN POTASSIUM 104 104 21 22
HYDROCHLOROTHIAZIDE 94 86 22 10
FAMOTIDINE 87 87 23 42
HYDROCODONE-ACETAMINOPHEN 77 71 S3 24 6
MEGESTROL ACETATE 74 74 R 25 165
DIGOXIN 70 70 26 43
TRIAMTERENE-HCTZ 69 69 27 53
ALLOPURINOL 66 66 28 33
NOVOLOG 66 66 28 127
POLYETHYLENE GLYCOL 3350 66 63 28 56
LOVASTATIN 65 59 31 30
CARBIDOPA-LEVODOPA 65 65 31 88
GLIMEPIRIDE 64 64 33 51
ATENOLOL 60 60 34 15
CRESTOR 60 55 34 25
TAMSULOSIN HCL 60 59 34 29
PANTOPRAZOLE SODIUM 59 59 37 34
FLUTICASONE PROPIONATE 57 57 38 39
SPIRIVA 55 55 39 54
PRAVASTATIN SODIUM 55 55 39 16
MELOXICAM 54 54 41 40
RANITIDINE HCL 53 37 42 24
ISOSORBIDE MONONITRATE ER 50 50 43 55
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 7, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.